Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

Naïve Human Stem Cells to Promote Research in Regenerative Medicine and Human Development

By BiotechDaily International staff writers
Posted on 14 Nov 2013
ADVERTISEMENT
SARTORIUS AG
Discovery of a method for maintaining human induced pluripotent stem cells (iPS cells) in their earliest, most primitive, naïve state is expected to promote research into their use in regenerative medicine, patient-specific iPS cell disease modeling, and the study of early human development in vitro and in vivo.

Induced pluripotent stem cells are usually created by inserting four genes into the genomes of such adult cells as skin cells and then culturing the modified cells with a cocktail of growth factors. The differentiated cells then revert to an embryonic-stem-cell-like state from which they can mature into a multitude of different cell types. The problem has been the lack of a method to hold the stem cells in the undifferentiated state for any length of time.

Investigators at the Weizmann Institute of Science (Rehovot, Israel) worked on this problem with both mouse and human cells. In particular, they were interested in establishing a technique to preserve human iPS cells in their earliest, naïve state that would mimic the behavior of mouse stem cells, which naturally remain in an undifferentiated state for much longer.

They reported in the October 30, 2013, online edition of the journal Nature that they had successfully established defined conditions that facilitated the derivation of genetically unmodified human naive pluripotent stem cells from already established primed human embryonic stem cells, from somatic cells through iPS cell reprogramming, or directly from blastocysts. The novel naïve pluripotent cells retained molecular characteristics and functional properties that were highly similar to mouse naive embryonic stem cells, and distinct from conventional primed human pluripotent cells.

"These cells correspond to the earliest stages of human embryonic stem cells that have been isolated. We managed to freeze what is essentially a very fleeting situation and to produce a new, naïve, pluripotent state in stem cells," said senior author Dr. Jacob H. Hanna, professor of medical genetics at the Weizmann Institute of Science. "When we grow the cells in the petri dish we do not know if they are maintaining their original state as in the embryo. This is what is new: this is the first time that we can keep the cells in what we call the naïve configuration. The challenge for us now is how to take these naïve cells and in the petri dish make a liver, or, from our study, it starts creating the possibility that with these cells you may consider growing organs in other species. We do not know if that works. There are a lot of ethical issues to consider. But we have put this on the table."

Related Links:

Weizmann Institute of Science



Channels

Drug Discovery

view channel
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).

Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins. Asparagine (N)-linked glycosylation... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.